1. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571);La Rosée;Cancer Res.,2002
2. Huron, D.R. et al. A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-abl driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin. Cancer Res. (in press)